Nucleoside analogues and other investigational modalities for the treatment of chronic hepatitis B.
Fried
M W
MW
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Sommadossi
J P
JP
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D000077595:Famciclovir; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D014740:Vidarabine / Q000627:therapeutic use
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D001086:Arabinofuranosyluracil; D015075:2-Aminopurine; D012254:Ribavirin; C043457:fialuridine; D014740:Vidarabine; D000077595:Famciclovir